Automated Cell Culture Market Trends

Growth Drivers

• Rising Incidence of Chronic and Infectious Diseases- Finding and developing effective therapies and medications for infectious and chronic diseases requires significant research and development efforts. The automated cell culture market is expanding as a result of the rise in long-term illnesses like HIV, TB, and cancer. Automated cell culture helps with drug research and development as well as the knowledge of the causes and mechanisms of these diseases. It enhances the well-being and standard of living for individuals with genetic disorders and cancer patients. Seven in ten US deaths occur from chronic conditions each year, according to the CDC. Six out of ten Americans suffer from at least one chronic illness, such as diabetes, heart disease, stroke, or cancer. Roughly 10 million deaths, or roughly one in six deaths, globally will be attributable to cancer in 2020. The increase in chronic illness cases will have a beneficial effect on the automated cell culture market expansion.
• Technological Advancement- Excellent consistency in 3-D cultures has been achieved by automation. There are several reasons why 3D cell culture is gaining traction over 2D culture. On flat surfaces, 2D cell culture techniques are used to grow cells as 2D monolayers. However, the fact that these cells only attach to and adhere to cells at the edge of cell culture vessels poses a limitation to multi-dimensional cell culture. Researchers have come up with a way to deal with these issues: 3D cell culturing. Numerous studies on fundamental biological systems, such as cell survival, proliferation, number monitoring, and morphology, have demonstrated the effectiveness of these cultures. Furthermore, compared to 2D culture, 3D cell culture exhibits better stability and longer lifespans.
• Growing Focus on Regenerative Medicines- It looks like the cutting-edge science of regenerative medicine may open doors for treating underlying conditions like incurable diseases. Hitachi has adopted an open innovation policy and worked with partners in academia and the pharmaceutical industry to develop automated cell culture technologies for therapeutic cells. Because Hitachi's automated cell culture method is a closed system, it has an advantage. Automating the current manual cell production procedures will enable the production of cells at a reasonable cost. Applications of regenerative medicine that use donor-induced pluripotent stem cells and may provide long-lasting therapy may benefit a large number of patients. Autologous regenerative medicine, or autologous cell transplantation, is another potentially more promising area that enhances the patient quality of life because of its incredibly low risk of immune rejection. Given that autologous transplantation involves patient-specific cell conditions, Hitachi's intelligent automated cell culture equipment ought to be a helpful resource.

Challenges

• Higher cost associated with automated cell culture- Research centers and organizations need to invest heavily to automate cell culture. In addition, the stringent production guidelines necessary to obtain market certification for the equipment from many governmental bodies raise the cost of these systems. Furthermore, the integration of information technology (IT) into laboratory automation instruments requires significant production expenditures, leading to increased equipment expenses. The significant upfront and recurring expenses associated with automated cell culture are expected to limit the global market's growth since small-scale research labs and organizations cannot afford to construct such costly equipment.
• It is projected that the market growth will be hindered throughout the assessment period by the need for increased awareness and a shortage of skilled experts.
• Development and maintenance of expertise may hinder the growth of the market.